Get started
Author

Stephan T F M Frequin

Observed names: Frequin, S. T. F. M., Frequin, S. T.F.M., Frequin, S.T.F.M., Frequin, Stephan, S T F M Frequin, S T Frequin, S. Frequin, S. T. F. M. Frequin, S. T.F.M. Frequin, S.T.F. Frequin, S.T.F.M. Frequin, STFM Frequin, Stephan Frequin, Stephan T. F. M. Frequin, Stephan T.F.M. Frequin, Stephan TFM Frequin, Stfm Frequin
Observed institutions: University Medical Center Groningen, Radboud University Nijmegen, Vita-Salute San Raffaele University, Society for Vascular Surgery, Radboud University Medical Center, Society of Interventional Radiology, St. Antonius Ziekenhuis, IRCCS Ospedale San Raffaele, UCL Queen Square Institute of Neurology
ORCID: 0000-0001-6805-5073
Observed ORCID: 0000-0001-6805-5073
OpenAlex ID: A5072236668
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
2018 · Raju Kapoor, Pei-Ran Ho, et al. · The Lancet Neurology · 333
PDF
Correlating MRI and clinical disease activity in multiple sclerosis
1995 · M.A.A. van Walderveen, F. Barkhof, et al. · Neurology · 294
Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
1992 · F Barkhof, P Scheltens, et al. · American Journal of Roentgenology · 165
Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis
1994 · M.A.A. van Walderveen, M. W. Tas, et al. · Neurology · 120
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial
2022 · John F Foley, Gilles Defer, et al. · The Lancet Neurology · 118
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
2013 · M. Filippi, M. A. Rocca, et al. · Journal of Neurology Neurosurgery & Psychiatry · 113
A correlative triad of gadolinium‐DTPA MRI, EDSS, and CSF‐MBP in relapsing multiple sclerosis patients treated with high‐dose intravenous methylprednisolone
1992 · F. Barkhof, S. T.F.M. Frequin, et al. · Neurology · 111
MRI pattern in asymptomatic natalizumab-associated PML
2014 · Mike P Wattjes, Anke Vennegoor, et al. · Journal of Neurology Neurosurgery & Psychiatry · 94
PDF
Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis
1994 · F. Barkhof, M. W. Tas, et al. · Neuroradiology · 56
Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS
2017 · Mike P Wattjes, Martijn T Wijburg, et al. · Journal of Neurology Neurosurgery & Psychiatry · 44
CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone
1992 · S. T. F. M. Frequin, F. Barkhof, et al. · Acta Neurologica Scandinavica · 44
Magnetic Resonance Imaging of Epilepsy in Multiple Sclerosis: A Case Control Study. Implications for Treatment Trials with 4-Aminopyridine
1996 · L Truyen, F Barkhof, et al. · Multiple Sclerosis Journal · 38
Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal study
2019 · Dennis A.M. van Gorp, Karin van der Hiele, et al. · Neurological Sciences · 34
PDF
Daily negative interactions and mood among patients and partners dealing with multiple sclerosis (MS): The moderating effects of emotional support
2006 · Annet M. Kleiboer, Roeline G. Kuijer, et al. · Social Science & Medicine · 34
The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis
1992 · Stephan T.F.M. Frequin, Frederik Barkhof, et al. · Journal of Neuroimmunology · 34
The capability set for work – correlates of sustainable employability in workers with multiple sclerosis
2018 · D. A. M. van Gorp, J. J. L. van der Klink, et al. · Health and Quality of Life Outcomes · 32
PDF
Patterns of Brain Magnetic Resonance Abnormalities on T2-Weighted Spin Echo Images in Clinical Subgroups of Multiple Sclerosis: A Large Cross-Sectional Study
1998 · Marianne A.A. van Walderveen, Frederik Barkhof, et al. · European Neurology · 30
Real-Time Assessment of Fatigue in Patients With Multiple Sclerosis: How Does It Relate to Commonly Used Self-Report Fatigue Questionnaires?
2016 · Martin Heine, Lizanne Eva van den Akker, et al. · Archives of Physical Medicine and Rehabilitation · 28
Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone
1993 · Stephan T. F. M. Frequin, Ron A. Wevers, et al. · Journal of Neurology · 27
Follow-up study of MS patients treated with high-dose intravenous methylprednisolone
2009 · S. T. F. M. Frequin, K. J. B. Lamers, et al. · Acta Neurologica Scandinavica · 25
Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study
2014 · The FOCUS Extension Study Group, Peter Joseph Jongen, et al. · Journal of Neurology · 24
PDF
Development of an international, multidisciplinary, patient-centered Standard Outcome Set for Multiple Sclerosis: The S.O.S.MS project
2022 · K. Daniels, S.T.F.M. Frequin, et al. · Multiple Sclerosis and Related Disorders · 19
PDF
Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis
2020 · K. Daniels, P. B. van der Nat, et al. · Multiple Sclerosis International · 19
PDF
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
2018 · Maria Trojano, Helmut Butzkueven, et al. · Multiple Sclerosis and Related Disorders · 19
PDF
T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolne
2009 · S. T. F. M. Frequin, K. J. B. Lamers, et al. · Acta Neurologica Scandinavica · 19
Works count: 78
Citation count: 2,126
H-index: 21
I10-index: 39
Year
Topic
Type